Stock Events

Stock Events

Cytosorbents 

0
20
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 12Expected
Q2 2026
Next
-1.21
-1.07
-0.93
-0.78
Expected EPS
-0.801072
Actual EPS
N/A

Financials

-22.07%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
32.18MRevenue
-7.1MNet Income

Analyst Ratings

$7.21Average Price Target
The highest estimate is ⁦7.21⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HQE.STU. It's not an investment recommendation.
Rigetti Computing
6
RGTI
Teucrium Wheat Fund
5
WEAT
Realty Income
4
O
NVIDIA
4
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Baxter International
BAX
Mkt Cap11.9B
Baxter International offers a range of dialysis products and acute therapies, directly competing with Cytosorbents' blood purification solutions.
Medtronic
MDT
Mkt Cap123.49B
Medtronic offers products for dialysis and blood management, competing in the broader market of medical devices for critical care, similar to Cytosorbents.
Danaher
DHR
Mkt Cap163.25B
Danaher Corporation, through its subsidiary Cytiva, provides products and services for life sciences research, competing in the bioprocessing space with Cytosorbents.
Boston Scientific
BSX
Mkt Cap60.84B
Boston Scientific Corporation competes in the medical devices sector, offering products that could be used in similar clinical settings as Cytosorbents' therapies.
Stryker
SYK
Mkt Cap111.95B
Stryker Corporation manufactures medical devices and equipment, including products for intensive care, which could be seen as complementary or competitive to Cytosorbents' offerings.
Abbott Laboratories
ABT
Mkt Cap183.77B
Abbott Laboratories offers a wide range of medical devices, diagnostics, and nutritional products, competing in the broader healthcare and medical device market.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its medical devices segment, competes across various healthcare sectors, including areas relevant to Cytosorbents' market.
Edwards Lifesciences
EW
Mkt Cap53.03B
Edwards Lifesciences specializes in heart valves and hemodynamic monitoring, competing in the critical care space where Cytosorbents operates.
SeaStar Medical
ICU
Mkt Cap11.78M
ICU Medical provides infusion therapy and critical care products, competing in the market for medical devices and technologies for critical patient care.

About

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Show More
CEO
Phillip Chan
Employees
129
Country
United States
ISIN
US23283X3052
WKN
000A42KBG

Listings

BOATS
BOATS
CTSO.BOATS
MU
DE
HQE1.MU
F
DE
HQE.F
MU
DE
HQE.MU

0 Comments

Share your thoughts

FAQs

What is Cytosorbents stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Cytosorbents stocks are traded under the ticker HQE.STU.
When is the next Cytosorbents earnings date?▼
Cytosorbents is going to release the next earnings report on November 12, 2026.
What were Cytosorbents earnings last quarter?▼
HQE.STU earnings for the last quarter are -1.21 EUR per share, whereas the estimation was -0.78 EUR resulting in a -55.56% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Cytosorbents revenue for the last year?▼
Cytosorbents revenue for the last year amounts to 32.18M EUR.
What is Cytosorbents net income for the last year?▼
HQE.STU net income for the last year is -7.1M EUR.
How many employees does Cytosorbents have?▼
As of November 5, 2026, the company has 129 employees.
In which sector is Cytosorbents located?▼
Cytosorbents operates in the Health & Wellness sector.
When did Cytosorbents complete a stock split?▼
The last stock split for Cytosorbents was on September 8, 2026 with a ratio of 1:20.
Where is Cytosorbents headquartered?▼
Cytosorbents is headquartered in PRINCETON, United States.